Europe’s medicines regulator is expecting higher-than-anticipated staff departures as a result of its Brexit-induced move from London to Amsterdam next year.
Britain’s pharma trade body has issued a fresh Brexit warning, saying it would be disadvantageous to both the UK and the EU if drugs regulation diverges as a result of the political changes
Biogen and AbbVie have announced the voluntary withdrawal of their multiple sclerosis drug Zinbryta from all markets worldwide following dangerous brain inflammation in seven patients in Eu
